The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03401827 |
Recruitment Status : Unknown
Verified January 2018 by Sang Hyub Lee, Seoul National University Hospital.
Recruitment status was: Recruiting
First Posted : January 17, 2018
Last Update Posted : February 12, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Adenocarcinoma Chemotherapy Effect | Drug: Chemotherapy (Gemcitabine + nab-paclitaxel) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer |
Estimated Study Start Date : | March 1, 2018 |
Estimated Primary Completion Date : | January 1, 2019 |
Estimated Study Completion Date : | January 1, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Gemcitabine + nab-paclitaxel
Case with chemotherapy (Gemcitabine + nab-paclitaxel)
|
Drug: Chemotherapy (Gemcitabine + nab-paclitaxel)
Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15 Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15 Other Name: GnP |
- survival rate [ Time Frame: 6 months ]survival rate at 6 months after 2nd line chemotherapy
- overall survival [ Time Frame: till death or follow-up loss or end of study up to 2 years ]overall survival after 2nd line chemotherapy
- Progression free survival [ Time Frame: till death or follow-up loss or end of study up to 2 years ]duration till progression after 2nd line chemotherapy
- Disease control rate [ Time Frame: 6 months ]SD (stable disease) + PR (partial response) + CR (complete response) after 2nd line chemotherapy
- adverse event [ Time Frame: till death or follow-up loss or end of study up to 2 years ]all reported adverse events after 2nd line chemotherapy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
-
Inclusion criteria
- Patient whose age is 20 years or older
- ECOG Performance Status 0-2
- Pathologically confirmed pancreatic adenocarcinoma
- Patients with locally advanced or distant metastasis status
- Patients who had undergone primary chemotherapy with previous FOLFIRINOX and whose disease progress was confirmed
- Patients whose consent was obtained (non-insurance agreement)
-
Exclusion Criteria
- Those who can not obtain consent
- Those who refuse chemotherapy
- ECOG Performance Status 3 or higher
- Multiple organ failure is accompanied
- Severe comorbidities other than cancer that do not expect a sufficient survival period over 1 month
- Allergy to the test drug
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03401827
Contact: Jin Ho Choi, MD | 82-2-2072-2228 | pseudo.jh@gmail.com | |
Contact: Sang Hyub Lee, MD, Ph.D | 82-2-2072-2228 | gidoctor@korea.com |
Korea, Republic of | |
Seoul National University Hospital | Recruiting |
Seoul, Korea, Republic of, 110-744 | |
Contact: Sang Hyub Lee, MD. PhD. +82-2-2072-4892 gidoctor@snuh.org |
Study Director: | Sang Hyub Lee, MD, Ph.D | Seoul National University Hospital |
Responsible Party: | Sang Hyub Lee, Professor, Seoul National University Hospital |
ClinicalTrials.gov Identifier: | NCT03401827 |
Other Study ID Numbers: |
H-1710-067-894 |
First Posted: | January 17, 2018 Key Record Dates |
Last Update Posted: | February 12, 2018 |
Last Verified: | January 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
pancreatic cancer second line chemotherapy nab-paclitaxel |
Pancreatic Neoplasms Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Paclitaxel |
Gemcitabine Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites |